(0.01%) 5 479.25 points
(0.00%) 38 819 points
(0.06%) 19 933 points
(0.29%) $80.56
(1.15%) $2.82
(0.08%) $2 330.80
(-0.43%) $29.27
(-0.15%) $969.40
(0.03%) $0.932
(-0.11%) $10.64
(0.08%) $0.788
(-1.86%) $86.80
Live Chart Being Loaded With Signals
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States...
Stats | |
---|---|
Šios dienos apimtis | 64 126 |
Vidutinė apimtis | 229 541 |
Rinkos kapitalizacija | 200.47M |
EPS | $-0.400 ( Q3 | 2023-11-07 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-6.38 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.270 (4.65%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-10-10 | Mcfarlane Neil F. | Buy | 600 000 | Stock Option (right to buy) |
2023-10-10 | Mcfarlane Neil F. | Buy | 200 000 | Restricted Stock Unit |
2023-10-10 | Mcfarlane Neil F. | Buy | 0 | |
2023-09-05 | Schafer Joshua | Buy | 500 | Common Stock |
2023-09-06 | Clifton R. Laduane | Buy | 1 000 | Common Stock |
INSIDER POWER |
---|
97.21 |
Last 89 transactions |
Buy: 4 356 177 | Sell: 72 592 |
Tūris Koreliacija
KemPharm Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
KemPharm Inc Koreliacija - Valiuta/Žaliavos
KemPharm Inc Finansinės ataskaitos
Annual | 2022 |
Pajamos: | $10.46M |
Bruto pelnas: | $10.12M (96.72 %) |
EPS: | $-1.200 |
FY | 2022 |
Pajamos: | $10.46M |
Bruto pelnas: | $10.12M (96.72 %) |
EPS: | $-1.200 |
FY | 2021 |
Pajamos: | $28.65M |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-2.15 |
FY | 2020 |
Pajamos: | $13.29M |
Bruto pelnas: | $11.98M (90.18 %) |
EPS: | $-3.21 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
KemPharm Inc
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077 which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase I clinical trial. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. KemPharm, Inc. has collaboration and license agreement, with KVK-Tech, Inc. and Commave Therapeutics SA. The company was incorporated in 2006 and is headquartered in Celebration, Florida.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.